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Oncolytic adenoviruses (OAds) are very promising for the treatment of lung cancer. However, OAd-based
monotherapeutics have not been effective during clinical trials. Therefore, the effectiveness of vir-
otherapy must be enhanced by combining OAds with other therapies. In this study, the therapeutic
potential of OAd in combination with temozolomide (TMZ) was evaluated in lung cancer cells in vitro and
in vivo. The combination of OAd and TMZ therapy synergistically enhanced cancer cell death; this
enhanced cancer cell death may be explained via three related mechanisms: apoptosis, virus replication,
and autophagy. Autophagy inhibition partially protected cancer cells from this combined therapy. This
combination signiﬁcantly suppressed the growth of subcutaneous H441 lung cancer xenograft tumors in
athymic nude mice. In this study, we have provided an experimental rationale to test OAds in combi-
nation with TMZ in a lung cancer clinical trial.
& 2015 Elsevier Inc. All rights reserved.Introduction
Lung cancer remains the leading cause of death from cancer
worldwide (Murray and Lopez, 2013). Most chemotherapy and
molecular therapies are based on the induction of apoptosis.
However, tumors frequently develop resistance to apoptosis prior
to or during cancer treatment (Zhang et al., 2006). Temozolomide
(TMZ), an alkylating agent in monotherapy or in association with
irinotecan, has been tested as a second- (or third-) line therapy in
patients with non-small cell lung carcinoma (NSCLC). TMZ is,
however, associated with low response rates (Tatar et al., 2013),
which may be due to increased expression of the DNA repair
enzyme, O6-methylguanine-DNA methyltransferase (MGMT), in
NSCLC tumors (Mattern et al., 1998).
One very promising approach for the treatment of lung cancer
tumors is the use of oncolytic adenoviruses (OAds). OAds-based
monotherapeutic clinical trials, however, have not met expecta-
tions. Therefore, the effectiveness of oncolytic virotherapy must be
enhanced with the combination of other therapies (i.e., che-
motherapy or immunotherapy).anslational Research (KCCTR)
ouisville, KY 40202, USA.
z-Gutierrez).The combination of oncolytic adenoviruses and TMZ sig-
niﬁcantly enhanced the melanoma and glioblastoma antitumor
response in vitro and in vivo (Jiang et al., 2015; Kaliberova et al.,
2009). This enhanced antitumor response was due to autophagy
induction by TMZ (Tyler et al., 2009; Ulasov et al., 2009a).
Autophagy involves the degradation of unnecessary or dysfunc-
tional cellular components. The breakdown of cellular components
can ensure cellular survival during starvation and stress by
maintaining cellular energy levels (Newman et al., 2007). Autop-
hagy has a dual role, acting as a survival mechanism and as a
caspase-independent form of programmed cell death (Gozuacik
and Kimchi, 2007).
There are two types of lung cancer cells in terms of OAds
replication efﬁciency: permissive or semi-permissive. Oncolytic Ad
replication is greater in permissive cancer cells than in semi-
permissive cancer cells (Hay et al., 1999). Therefore, to improve the
therapeutic efﬁcacy of OAds to treat heterogeneous NSCLC tumors,
OAds replication must be enhanced in both permissive and semi-
permissive lung cancer cells. In this study, we investigated
whether TMZ-induced autophagy could enhance virotherapy in
both permissive and semi-permissive lung cancer cells. The com-
bination of OAd and TMZ therapy was highly effective in vitro
and in vivo.
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Evaluation of virotherapy and chemotherapy killing effect on per-
missive and semi-permissive lung cancer cells
Multiple lung cancer cell lines were infected with the following
two adenoviruses: adenovirus serotype 5 wild type (Adwt) and
E1B-deleted Adhz60 (Adhz60). At 72 h post-infection, crystalFig. 1. Evaluation of oncolytic adenovirus-mediated cytopathic effect in permissive and no
bitory concentration (IC50). (A) Permissive H1299 and A549 or semi-permissive Calu1 and
infection (MOI) concentration of 0, 1, 2.5, 5, 10, and 20. At 72 h post-infection, crystal viole
of three experiments performed. (B) Cell viability was calculated by measuring the ab
independent experiments7standard deviation (SD; bars). (C) The cell lines above-men
0.75, and 1 mM. A MTT assay was used to determine cell survival at 72 h post-treatme
deviation (SD; bars). (D) Human lung cancer cell lines were treated with Adhz60 and TM
Calu1 (10 MOI, 1 mM), and H441 (20 MOI, 0.75 mM). AdLacZ was used at 10 MOI for all
Cytotoxic effect was evaluated as described in (A). Results represent the mean of three
lines). (E) The quantitated cell viability data were analyzed by CalcuSyn software. The X
groups. The middle curve line represents the simulated combination index values of the
the 95% conﬁdence intervals.violet staining revealed that cytopathic effects (CPE) increased in a
virus dose-dependent manner (Fig. 1A). Sensitivity to Adwt and
Adhz60 was variable across these cancer cell lines. Furthermore,
the estimated half maximal inhibitory concentration (IC50) of
Adwt ranged from a multiplicity of infection (MOI) concentration
of 1 to 10, depending upon the cancer cell line. Adhz60 efﬁciently
induced CPE in H1299 and A549 cells at low MOI concentrations
(1 and 3, respectively) (Fig. 1A). In contrast, the semi-permissiven-permissive lung cancer cells and determination of temozolomide half maximal inhi-
H441 lung cancer cell lines were infected with Adwt or Adhz60 at a multiplicity of
t staining was used to evaluate cytopathic effect. A representative staining is shown
sorbance of solubilized dye at 590 nm. Each point represents the mean of three
tioned were treated with temozolomide (TMZ) at concentratons of 0, 0.1, 0.25, 0.5,
nt. Each point represents the mean of three independent experiments7standard
Z at the following doses for Adhz60 and TMZ, respectively: A549 (2.5 MOI, 0.6 mM),
cell lines. DMSO was added as a control at its respective volume for each cell line.
repeated measurements7standard deviation (SD; error bars) (*po0.05 for all cell
-marks represent the combination index (CI) values of the combination treatment
combination treatment groups surrounded by two lines of algebraic estimations of
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both Adwt and Adhz60. Adhz60 IC50 for Calu-1 cells was reached
at an 10 MOI, whereas the IC50 was approximately reached at 20
MOI for H441 cells (Fig. 1B). Adwt could induce IC50 in Calu-1 and
H441 cells, but at greater rates of MOI (5 and 10, respectively) in
comparison with permissive cancer cells, in which IC50 was a rate
less than 1 MOI (Fig. 1B). Next, the TMZ IC50 was determined. Lung
cancer cell lines were treated at increasing TMZ concentrations. At
72 h post-treatment, an MTT assay revealed that cell viability
inhibition increased in a dose-dependent manner with increasing
TMZ concentration. Sensitivity to TMZ was also variable across
cancer cell lines. Calu-1 showed greater resistance to TMZ. The IC50
of TMZ in H441 and A549 cells was at 1 and 0.75 mM, respectively.
In Calu1 and H1299, the IC50 of TMZ was not reached under this
experimental condition (Fig. 1C).Fig. 2. Evaluation of apoptosis induction. Whole cell protein lysates were collected 72 h
cleaved caspase-3 was detected. (B) A549, H441, and Calu1 lung cancer cells were staine
V-PE and 7-AAD staining were analyzed by FACScan ﬂow cytometer with FlowJo softw
deviation (SD; error bars) (*Po0.05).The combined therapy of Adhz60 with TMZ resulted in a synergistic
lung cancer killing effect
The effect of the combination of Adhz60 and TMZ upon cell
viability was analyzed for synergy. Adhz60 at 1 MOI efﬁciently
destroyed H1299 cells as shown in Fig. 1A; therefore, H1299 cells
were removed from further experimentation.
Lung cancer cell lines were infected with Adhz60 at their
respective IC50 doses in combination with their respective TMZ IC50
doses. DMSO was added at its respective volume as control. At 72 h
post-treatment, crystal violet staining results showed that the
combination of Adhz60 and TMZ (Adhz60þTMZ) induced greater
cytotoxicity in all three cancer cell lines treated than in the onco-
lytic virus or TMZ treatments alone (Fig. 1D) (Supplementary 1).
We then evaluated these quantitated data by fraction affected ver-
sus combination index (Fa–Cl) with CalcuSyn software to assess ifafter indicated treatment (mock, AdLacZþTMZ, Adhz60þTMZ). (A) Expression of
d with annexin V-PE and 7-aminoactinomycin D (7-AAD). Positive cells for annexin
are. (C) Results represent the mean of three independent experiments7standard
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(Biosoft, Ferguson, MO) (Fig. 1E). The cell viability was signiﬁcantly
lower with the combination of Adhz60þTMZ than with Adhz60
alone, TMZ alone, with replication-incompetent AdLacZ expressing
β-galactosidaseþTMZ, or with controls (mockþAd-LacZ) (Fig. 1D).
The middle curve line represents the simulated combination index
values of the combination treatment groups surrounded by two
lines of algebraic estimations of the 95% Conﬁdence Intervals. Most
of the experimental CI values at the tested ratio were o1 and
between the two Conﬁdence lines, indicating synergism ofFig. 3. Effect of temozolomide (TMZ) on oncolytic adenovirus replication in permissive, n
described in Fig. 1. Seventy-two hours post-treatment, supernatants were collected and u
three independent experiments7standard deviation (SD; error bars) (*Po0.05). (B)
Expression of adenovirus E1A was detected by Western blot analysis. The values indi
(C) MRC-5 cells were not infected (mock) or infected at a multiplicity of infection (MOI) c
of TMZ. (D) Seventy-two hours post-treatment, cell viability was calculated by measurin
three independent experiments7standard deviation (SD; bars). (E) Release of infectiou
three independent experiments7standard deviation (SD; error bars) (*Po0.05). (F) Excombination treatments (po0.05) (Fig. 1E). These results indicate
that the combination therapy (Adhz60þTMZ) resulted in syner-
gistic cytotoxicity in multiple human lung cancer cell lines.The synergistic killing effect of combined therapy using oncolytic
adenovirus and TMZ was, in part, due to apoptosis
The activation of caspase-3 was evaluated next. Immunoblot
analysis revealed greater expression of cleaved caspase-3 in cells
treated with Adhz60þTMZ than in either treatment aloneon-permissive, and lung non-cancerous cells. (A) Lung cancer cells were treated as
sed to determine adenovirus yield from each cell line. Results represent the mean of
Whole cell protein lysates were collected at 72 h following indicated treatment.
cate the ratios of normalized band intensities of E1A expression proﬁles to actin.
oncentration of 5 with AdLacZ, Adhz60, or Adwt followed by DMSO (6 ml) or 0.6 mM
g the absorbance of solubilized dye at 590 nm. Each point represents the mean of
s virus particles was determined as described in (A). Results represent the mean of
pression of adenovirus E1A was detected by Western blot analysis.
Fig. 4. Evaluation of temozolomide (TMZ) ability to induce autophagy in lung cancer cells, enhanced autophagy using combination therapy, and the effect of autophagy inhibition
using combined therapy-mediated cytotoxicity. (A) Lung cancer cells were transfected with pEGFP-LC3 followed by DMSO (A549: 6 ml; H441: 7.5 ml; and Calu1: 10 ml) or TMZ
(A549: 0.6 mM; H441: 0.75 mM; Calu1: 1 mM) treatments. Integration of GFP-LC3 into the autophagosome is depicted by punctate structures and was analyzed by
ﬂuorescence microscopy at 48 h post-treatment. Images were taken at 40 magniﬁcation with the EVOS FL Imaging System (Advanced Microscopy Group) under 357/
44 (nm) and 447/60 (nm) excitation and emission visualization. The percentage of cells with GFP punctuate pattern was calculated as punctuate GFP cell per total GFP cell %.
A representative experiment showing punctuation (arrows) is shown from three performed. (B) LC3 expression and modiﬁcation were analyzed in a time course assay.
(C) Human lung cancer cell lines were treated with Adhz60 and TMZ alone or in combination at the following doses for Adhz60 and temozolomide (TMZ), respectively: A549
(2.5 MOI, 0.6 mM), Calu1 (10 MOI, 1 mM), and H441 (10 MOI, 0.75 mM). DMSO was added as a control at its respective volume for each cell line. Expression of LC3-I, LC3-II,
and p62 were evaluated by Western blotting. Actin was used as a loading control. The values indicate the ratios of normalized band intensities of LC3I and LC3II or p62
expression proﬁles to actin. A representative experiment is shown. (D) A549 cells were cultured in the presence or absence of either 3-MA (10 mM) or BAF-A1 (10 nM).
Media containing the drug was removed the next day, and the cells were treated with Adhz60 at a multiplicity of infection (MOI) concentration of 10 or TMZ at 0.75 mM,
both for single and combined treatments. Seventy-two hours post-treatment, cell viability was evaluated by MTT assay. Results represent the mean of three independent
experiments7standard deviation (SD; error bars) (*Po0.05).
J.G. Gomez-Gutierrez et al. / Virology 487 (2016) 249–259 253
J.G. Gomez-Gutierrez et al. / Virology 487 (2016) 249–259254(Fig. 2A). Additionally, annexin V staining also showed a greater
proportion of apoptotic cells when treated with the combination
of both Adhz60 and TMZ than in either treatment alone (Fig. 2B).
In A549 cells, Adhz60 and TMZ induced 14% and 26% of apoptosis,
respectively, whereas the combined therapy resulted in 60% of
apoptosis (Fig. 2C). In H441 cells, Adhz60 and TMZ induced 13%
and 14% of apoptosis, respectively, whereas the combination
therapy resulted in a 30% of apoptosis (Fig. 2C). In Calu1 cells,
Adhz60 and TMZ induced 10% and 13% apoptosis, respectively,
whereas the combination of both induced 32% apoptosis (Fig. 2C).
These results suggest that the synergistic killing effect of lung
cancer cells by TMZ along with Adhz60 is, at least in part, due to
greater apoptosis induction within these cells.
TMZ enhances virotherapy by increasing virus replication in lung
cancer but not in non-cancerous lung cells
Lung cancer cell lines were treated as described in the Fig. 1.
Three days after treatment, samples were collected and adeno-
virus production was determined via the TCID50 protocol using
HEK293 cells. TMZ increased Adhz60 virus production approxi-
mately 100 fold in all three cancer cell lines tested compared to
Adhz60-infected cells treated with the TMZ drug vehicle DMSO.
Conversely, the production of Adwt viruses did not increase in the
presence of TMZ compared with Adwt-infected cells in the pre-
sence of DMSO (Fig. 3A). Immunoblot analysis results showed that
TMZ increased E1A expression by Adhz60, but TMZ treatment did
not alter E1A expression via Adwt (Fig. 3B). This effect was prob-
ably caused by greater potency of Adwt in comparison with
Adhz60; therefore, E1A expression reached its expression peak
before TMZ could increase Adwt-mediated E1A expression.
Human lung non-cancerous MRC-5 cells were treated with the
combined therapy or the respective controls. A crystal violet
staining showed that Adhz60 alone did not induce CPE in MRC-5
cells. Most importantly, cells treated with Adhz60þTMZ did not
alter the induction of CPE in non-cancerous lung cells (Fig. 3C). In
contrast, Adwt alone induced signiﬁcant CPE in MRC5 non-
cancerous lung cells (58% of cell viability) (Fig. 3D). Adwt-
induced CPE was slightly increased in the presence of TMZ (52%
of cell viability) (Fig. 3D). Additionally, a virus titration assay
revealed that only Adwt-infected MRC-5 cells produced infective
virus particles in MRC5 non-cancerous cells (Fig. 3E). Finally, E1A
expression was dramatically lower in Adhz60-infected MRC5 non-
cancerous cells; TMZ treatment did not increase E1A expression in
these cells. Conversely, marked E1A expression was detected in
Adwt-infected MRC5 non-cancerous cells; TMZ treatment slightly
increased E1A expression by Adwt (Fig. 3F). These results suggest
that TMZ does not increase Adhz60-mediated oncolysis in MRC5
non-cancerous lung cells.
TMZ induces autophagosome formation and accumulation of LC3-II in
lung cancer cells
TMZ has been reported to induce autophagy in glioma cells (Lin
et al., 2012). Therefore, the ability of TMZ to induce autophagy in
lung cancer cells was evaluated. Lung cancer cells were transfected
with pEGFP-LC3 and treated with DMSO or TMZ and then
observed for the formation of cytoplasmic punctate GFP ﬂores-
cence. The conversion of cytoplasm-diffuse GFP-LC3-I to
membrane-associated GFP-LC3-II forms punctate patterns, indi-
cating LC3-II incorporation into the autophagosomes. This forma-
tion of punctate was observed at 48 h (Fig. 4A). TMZ induced
signiﬁcant GFP cellular puncta relative to DMSO-treated cells,
which exhibited diffuse cytoplasmic GFP-ﬂorescence and very few
punctate GFP expressing cells (8%). Among the lung cancer cell
lines, A549 showed the greatest percentage of cells with GFPpunctate pattern (57%), whereas Calu-1 and H441 had a lower
percentage (48% and 51%, respectively). These results suggest that
TMZ induces autophagy in lung cancer cells.
Next, the conversion of LC3-I to LC3-II, an autophagy maker
(Kabeya et al., 2000), was evaluated. Immunoblot analysis revealed
two reactive LC3 species: the upper band corresponding to LC3-I
(19 kDa) and a lower band corresponding to LC3-II (17 kDa).
Marked accumulation of LC3-II was observed in TMZ-treated cells
at 48 h and 72 h, whereas no conversion was observed in DMSO-
treated cells (Fig. 4B).
Combination of oncolytic adenovirus with temozolomide increases
autophagy
Since TMZ and Adhz60 are known to induce autophagy sepa-
rately (Lin et al., 2012; Rodriguez-Rocha et al., 2011), we investi-
gated whether the combination of both treatments could induce
greater autophagy than either treatment used alone. Lung cancer
cells were treated with TMZ or Adhz60 alone at their respective
IC50 or in combination; 72 h post-treatment, autophagy induction
was evaluated by LC3-I to LC3-II conversion and by the decreased
expression of p62, which is degraded during autophagy ﬂux
(Bjorkoy et al., 2005). Immunoblot analysis revealed a greater
accumulation of LC3-II in Adhz60þTMZtreated cells compared to
either treatment alone in all cell lines tested (Fig. 4C). The
decreased p62 expression was variable across these cancer cell
lines (Fig. 4C). These results suggest that the combination of
Adhz60 and TMZ induces greater autophagy in lung cancer cell
lines than either treatment alone.
Autophagy inhibition partially protects lung cancer cells from com-
bined therapy-mediated cell death
We assessed the cell killing effects of TMZ alone, Adhz60 alone,
or in combination, in the presence of 3-MA (Rodriguez-Rocha
et al., 2011) or Baf-A1 (Ulasov et al., 2009a), which are two agents
that inhibit autophagy by preventing the fusion of autophago-
somes and lysosomes (Yamamoto et al., 1998). 3-MA inhibits
autophagy during the formation of double-membrane structures,
and Baf-A1 inhibits the maturation of autophagosomes when the
cytosol is sequestered from the cytoplasm (Ravikumar et al., 2002).
In our study, TMZ-induced toxicity increased in the presence of
3-MA, whereas, in presence of Baf-A1, cell viability was unchan-
ged. The Adhz60-mediated cell death was signiﬁcantly decreased
by 3-MA and Baf-A1 treatments (Po0.05) (Fig. 4D). Most impor-
tantly, the combined treatment of Adhz60þTMZ was signiﬁcantly
impaired by the presence of 3-MA. This suggests that autophagy
may play a role in the combined therapy- mediated cell death.
Oncolytic adenovirus lacking the entire E1B activates p-JNK
The adenovirus E1B gene products have been reported to
strongly activate JNK (See and Shi, 1998), while TMZ was found to
have induced autophagy through JNK activation in glioma cells
(Lin et al., 2012). Because Adhz60 lacks the E1B gene, we hypo-
thesized that TMZ-induced JNK activation could complement the
lack of E1B-induced JNK activation, and virus replication would be
enhanced. However, we found that Adhz60 activated JNK alone
but TMZ did not in our experimental conditions. We hypothesized
that Adhz60 could induce p-JNK expression via E1A; however,
additional studies are necessary. The combination of both Adhz60
and TMZ appeared to result in a greater JNK activation at 48 h
(Fig. 5). These results suggest that TMZ does not activate JNK in
A549 lung cancer cells using these experimental conditions, and
that TMZ-mediated JNK activation may not be required to enhance
Adhz60 replication and oncolysis in A549 cells. This result is
Fig. 5. Evaluation of p-JNK, t-JNK, and E1A expressions in the combination therapy.
A549 human lung cancer cells were infected at a multiplicity of infection (MOI)
concentration of 2.5 alone or in combination with temozolomide (TMZ) at a
0.6 mM concentration. Expression of p-JNK, t-JNK, E1A, and actin were evaluated at
24 h and 48 h post-treatment by Western blot analysis. Actin was used as a loading
control. These values indicate the ratios of normalized band intensities of p-JNK to
actin expression. One representative experiment is shown.
Fig. 6. Assessment of MGMT expression. Human lung cancer cell lines were not
infected (mock) or infected with AdLacZ at a multiplicity of infection (MOI) con-
centration of 10 for all cell lines or Adhz60 at the following doses: A549 (2.5 MOI),
H441 (20 MOI), and Calu1 (10 MOI). Whole cell protein lysates were collected 72 h
after treatment. MGMT was detected by Western blot analysis. Actin was used as a
loading control. These values indicate the ratios of normalized band intensities of
MGMT to actin expression. One representative experiment from three is shown.
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played severely attenuated JNK activation, implicating the role of
E1A as a p-JNK inducer (See and Shi, 1998).
Adhz60 downregulates MGMT expression in lung cancer cells
MGMT is highly expressed in human cancers and confers resis-
tance to many clinically used alkylating agents such as TMZ
(Srivenugopal et al., 2001). It was reported that overexpression of
adenovirus E1A, which binds CBP/p300, strongly inhibited MGMT
promoter activity (Bhakat and Mitra, 2000). Therefore, we explored
the posibility that Adhz60 may decrease MGMT expression in lung
cancer cells via E1A-mediated sequestion of p300, which promotes
MGMT expression. Immunoblot analysis revealed that Adhz60
downregulated MGMT expression in all cancer cell lines; however,
MGMT downregulation was greatest in A549 cells. The negative
control AdLacZ did not affect MGMT expression (Fig. 6). These
results suggest that, although Adhz60 was able to decrease MGMT
expression, this effect might not be directly associated with the
synergistic effect of Adhz60 and TMZ combined.
Efﬁcient suppression of subcutaneous lung tumor growth in vivo by
the combination of Adhz60 and TMZ
The combination of Adhz60 and TMZ was further assessed for
its anti-tumor activity in vivo using a subcutaneous xenograftmurine model and H441 lung cancer cells. Mice bearing palpable
tumors were randomized and underwent intratumoral injection of
adenoviruses every three days for a total of four treatments; TMZ
was administered via intraperitoneal injection. Representative
tumors were harvested 24 h after the ﬁnal treatment following the
euthanasia of mice. Tumor samples were then subjected to his-
topathological analysis to assess whether adenovirus hexon
expression and apoptosis were possible mechanisms to induce
tumor suppression. Immunohistochemical analysis revealed that
hexon expression was detected in the Adhz60-treated group;
however, hexon expression appeared to increase following treat-
ment with the combination of Adhz60 and TMZ. Hexon was not
detected in AdLacZ-, TMZ-, and AdLacZþTMZ-treated groups.
Detection of cleaved caspase-3-positive cells was observed in
TMZ- and AdLacZþTMZ-treated groups, whereas it was not
detected in Adhz60 treated mice; however, a greater number of
cleaved caspase-3-positive cells were observed in the tumors of
mice treated with the combination of Adhz60þTMZ (Fig. 7A).
Greater tumor suppression was observed with combined
Adhz60 and TMZ treatment. Tumor sizes were approximately 41%
smaller in Adhz60-treated mice and 12% in TMZ-treated group,
whereas in Adhz60þTMZ treatment group, tumor sizes were
70% smaller compared to mice treated with the negative control
virus AdLacZ (Fig. 7B). The ﬁnal tumor volume was similar in the
negative control and TMZ treatment groups. The differences in
median tumor volumes at the conclusion of the experiment were
statistically signiﬁcant when comparing either treatment (TMZ or
Adhz60) alone to mice treated in combination (Adhz60þTMZ)
(*Po0.05). These results suggest that Adhz60 increases the sen-
sitivity of lung cancer cells to TMZ, and that lung cancer tumor
growth suppression by this therapeutic combination was, at least
in part, mediated by increased caspase activation in vivo.Discussion
TMZ has been reported to enhance oncolytic virotherapy in
glioblastoma and melanoma cells (Jiang et al., 2015; Kaliberova
et al., 2009). Additionally, oncolytic adenoviruses (OAds) have
been shown to sensitize glioma cells to TMZ by repressing the DNA
repair enzyme MGMT (Alonso et al., 2007). Other studies have
reported that autophagy plays a key role in oncolytic virotherapy
(Yokoyama et al., 2008), and that TMZ-induced autophagy
enhances OAd replication (Ulasov et al., 2009b). These synergistic
killing effects in glioblastoma were associated with the induction
of both autophagy and apoptosis in vitro and in vivo (Jiang et al.,
2013; Liikanen et al., 2013). Both reports found that virotherapy
was enhanced, in part, due to increased virus replication. There-
fore, we tested the ability of TMZ to enhance OAd virus replication
in lung cancer cells known to be permissive or semi-permissive to
Ad replication.
It was found that the combination therapy of Adhz60 with TMZ
has a synergistic killing effect in lung cancer cells (Fig. 1D and E).
This enhanced anti-cancer efﬁcacy may be explained by at least
three possible mechanisms: increased apoptosis, virus replication,
and autophagy. It was observed that TMZ did not further increase
E1A expression in Adwt infected-cells (Fig. 3B). This effect was
probably due to very high E1A expression by Adwt; therefore,
Adwt may have reached its peak E1A expression before TMZ could
increase Adwt-mediated E1A expression. Lower doses of Adwt or
an early time point might be explored to observe the effect of TMZ
in Adwt-infected cells.
More importantly, the combined therapy of Adhz60 and TMZ
displayed minor cytotoxicity upon non-cancerous MRC5 lung cells.
This suggests that the Adhz60-mediated killing effects were
dependent upon E1B gene deletion, regardless of drug-induced
Fig. 7. Evaluation of the therapeutic potential of combined therapy of Adhz60 with temozolomide in subcutaneous lung cancer mouse model. Flank lung cancer xenografts were
developed by injection of H441 human lung cancer cells subcutaneously. Therapy was initiated 7 days after tumor injection when palpable tumors were formed. Treatments
(n¼6) were as follows: Ad-LacZ (control), Adhz60, temozolomide (TMZ), AdLacZþTMZ, and Adhz60þTMZ. Virus therapy was delivered by intratumoral injection every
3 days for a total of 4 doses (vertical arrows). TMZ was administered by intraperitoneal injection daily for 5 days. Tumor volume (V) was plotted against time and was
determined by the equation V¼(LW2)/2, where L is the length and W is the width of the tumor. (A) Immunohistochemistry of excised tumor samples with hexon and
cleaved caspase-3 indicate increased hexon expression and apoptosis activation with combined treatment of Adhz60 and TMZ (Adhz60þTMZ). (B) Shows mean tumor
volumes over the 30-day experiment estimated by caliper measurements every 5 days. Tumor size differences between treatment groups were compared over the course of
the experiment using repeated measures ANOVA. Tumor sizes at the conclusion of the experiment were compared using one-way ANOVA, and post hoc testing of differences
between groups was adjusted for multiple comparisons using Tukey's HSD. Tumor size in the Adhz60þTMZ treatment group had signiﬁcantly decreased (SD; error bars)
(*Po0.05).
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toxicity in non-cancerous cells, suggesting a potentially favorable
therapeutic index for this combination.
The precise mechanism by which TMZ enhances Adhz60-
mediated oncolysis in lung cancer cells is not completely under-
stood. However, it was found that TMZ initiated autophagy in lung
cancer cells, and OAds may use TMZ-induced autophagy to increase
viral replication (Fig. 3A and B). We previously reported that inhi-
bition of autophagy with 3-methyladenine (3MA) resulted in a poor
viral replication, while the induction of autophagy with rapamycin
increased adenovirus yield (Rodriguez-Rocha et al., 2011). Herein,
we found a similar effect when 3MA or Baf-A1 were used to inhibit
the early and late phases of autophagy, respectively. This suggests
that autophagy may play a role in the enhanced lung cancer cell
death of these combined therapies. In fact, it was reported recently
that the addition of 3-MA suppresses TMZ-induced autophagy andincreases TMZ-induced apoptosis in glioma cells (Lin et al., 2012).
This suggests TMZ induces a protective autophagy.
As a monotherapeutic, TMZ-induced autophagy appears to
have a cytoprotective role. For example, TMZ can promote autop-
hagy through the accumulation of reactive oxygen species (ROS),
mitochondrial depolarization, and mitochondrial permeability
transition pore (MPTP) opening to cause mitochondrial damage,
resulting in protective autophagy (Lin et al., 2012). In this study,
we examined whether TMZ could activate JNK in lung cancer cells.
However, we were unable to detect p-JNK in A549 lung cancer
cells using these experimental conditions. Therefore, the precise
mechanism by which TMZ induces autophagy in lung cancer cells
remains unknown.
In summary, TMZ-induced autophagy provides a better cellular
environment for adenovirus replication. The combination of both
TMZ and Adhz60 enhances their potency reciprocally. This study
represents a potential alternative to lung cancer therapy, because
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may facilitate the virus spread within the lung tumors.Materials and methods
Cell lines and culture conditions
Human embryonic kidney 293 (HEK-293) cells, human lung
cancer permissive A549 & H1299 cells, semi-permissive H441 &
Calu-1, and human lung non-cancerous ﬁbroblast MRC-5 cell lines
were purchased from the American Type Culture Collection (Rock-
ville, MD). A549 and H1299 cells were grown in DMEM medium;
H441was cultured in RPMI1640 medium; Calu-1 in McCoy's 5a
medium; HEK-293 was grown in alpha-MEM medium. All media
were supplemented as previously described (Egger et al., 2014). All
cell culture reagents were obtained from Corning Cellgro.
Adenoviral vectors and drugs
A replication-deﬁcient adenoviral vector AdLacZ expressing β-
galactosidase under regulation of cytomegalovirus promoter was
used as a control as previously described (Egger et al., 2014). The
adenovirus serotype 5 wild type (Adwt) and a CRAd (Adhz60 E1B-
deleted) were used as previously reported by us (Rao et al., 2004).
TMZ and baﬁlomycin-A1 (Baf-A1) stock solutions of 100 mM and
1.6 mM, respectively, were prepared in dimethyl sulfoxide (DMSO)
and stored at 20 °C. 3-methyladenine (3-MA) was dissolved in
H2O at ﬁnal concentration of 66 mM. All drugs were purchased
from (Sigma-Aldrich, St Louis, MO).
Single and combined therapies
2.5104 cells were plated in 24-well plates and treated 24 h
later with indicated therapy. Viral infection was performed at an
indicated multiplicity of infection (MOI) concentration, whereas
TMZ treatment was performed at an indicated mM concentration.
Cytopathic effect (CPE) was evaluated with crystal violet staining
as described previously by our group (Cheng et al., 2015). Cell
viability was assessed 72 h after experimental therapy by mea-
suring the conversion the tetrazolium salt 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium (MTT) to formazan as described by
our group (Egger et al., 2014). For control infection, we used cell
line-speciﬁc media alone without virus or DMSO instead of TMZ.
The IC50 for both virus and TMZ were determined. For combined
therapies, cells were treated with Adhz60 and TMZ at their
respective IC50 doses. For inhibitory studies, A549 cells were see-
ded as described above. The next day, either 3-MA (10 mM)
(Rodriguez-Rocha et al., 2011; Ropolo et al., 2007) or BAF-A1
(10 nM) (Kanzawa et al., 2004) was added for further incubation.
The drug containing media was removed and cells were treated
with Adhz60 at an MOI of 10 or TMZ at 0.75 mM, both for single
and combined treatments. Seventy-two hours post-treatment, cell
viability was evaluated by MTT assay as described above.
Analyses of combined effects of Adhz60 and TMZ
The additive effect refers to a combined effect of drugs that
produces the sum of their individual effects. Synergism is the
combined effect of drugs which is greater than the sum of indi-
vidual effects. Antagonism is the combined effect of drugs which is
less than the sum of individual effects (Chou, 2006; Wang et al.,
2011). The combined effects of Adhz60 with TMZ on cell viability
were analyzed with the median-effect methods of Chou and
Talalay (Chou and Talalay, 1984) using CalcuSyn software (Biosoft,
Ferguson, MO). The combination index (CI) values were used toevaluate the interaction between the virus and drug. For the
fraction of virus affected combination index (Fa-CI) plot analysis, a
CIo1 is deﬁned as synergism, a CI¼1 is deﬁned as an additive
effect, and a CI41 is deﬁned as antagonism.
Annexin V staining and adenovirus titer analysis
Cells were stained with annexin V-PE and 7-AAD, according to
the manufacturer’s instructions (BD Pharmingen, San Diego CA).
Cells were analyzed by FACScan ﬂow cytometer (Becton Dickinson,
Franklin Lakes, NJ) and with FlowJo software (Tree Star Inc., Ash-
land, OR). For titer analysis, cells were treated as described in the
combined therapies. Seventy-two hours post-treatment, super-
natants were collected. Adenoviruses released were titered by
using a TCID50 end-point dilution method with HEK-293 cells
seeded on 96-well plates as described previously (Rodriguez-
Rocha et al., 2011).
Western blot analysis
Western blot analysis was performed using a standard proce-
dure as described previously (Rodriguez-Rocha et al., 2011). The
primary antibodies used were rabbit-antihuman cleaved caspase-
3, SQSTM1/p62 (D5E2), phospho-SAPK/JNK (Thr183/Tyr185) (p-
JNK) SAPK/JNK antibody total-JNK (t-JNK) (Cell Signaling, Danvers,
MA), rabbit anti-LC3 polyclonal antibody (Sigma-Aldrich, St Louis,
MO), mouse anti-adenovirus type 5 E1A (BD Pharmingen, San
Diego CA), and rabbit-antihuman-actin (Sigma-Aldrich, St Louis,
MO). The scanned band intensities were quantiﬁed using Gel-pro
Analyzer 4.0 software (Media Cybernetics) according to the man-
ufacturer’s tutorial. Densitometric values for each band were
expressed as integrated optical density (I.O.D.) and normalized to
actin expression.
GFP-LC3 puncta
Plasmid vector containing green ﬂuorescent protein (GFP)
linked to microtubule-associated protein 1 light chain 3 (LC3)
(Kabeya et al., 2000) was used to detect autophagosome formation
in lung cancer cell lines. At 24-h post-transfection, cells were
treated with DMSO or TMZ at its respective LD50 for each cell line.
At 48 h post-treatment, cells were examined under a ﬂuorescence
microscope. Cells were classiﬁed as having a predominantly dif-
fuse GFP stain or having numerous punctate structures repre-
senting autophagosomes. Images were taken at 40 magniﬁca-
tion with the EVOS FL Imaging System (Advanced Microscopy
Group) under 357/44 (nm) and 447/60 (nm) excitation and emis-
sion visualization. The percentage of cells with GFP puncta were
calculated as the proportion of cells with GFP puncta divided by
the total number of GFP expressing cells.
Mouse lung cancer xenograft model
Subcutaneous tumors were formed in the ﬂanks of 6-week-old
athymic BALB/c nu/nu male mice (Charles River Laboratories) by
injecting 5106 H441 human lung cancer cells in 100 mL of
phosphate buffered saline (PBS). Seven days following injection,
palpable tumors were formed. Treatment groups were as follows:
AdLacZ, TMZ, AdLacZþTMZ, Adhz60, and Adhz60þTMZ. Mice
were randomized and injected in the ﬂank with Adhz60
(1109 pfu (plaque forming units)) or Ad-LacZ (1109 pfu) (n¼6
for each group) intratumorally every three days for a total of four
treatments. TMZ was administered via intraperitoneal injections of
50 mg/kg (diluted in PBS) daily for ﬁve consecutive days. Tumor
size was measured with calipers in two dimensions (length and
width) every three days for 30 days, and tumor volume was
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V ¼ L x W2
 
=2
where V is volume, L is length and W is width. Animal
experiments were performed in accordance with institutional
guidelines and were approved by the University of Louisville
Institutional Animal Care and Use Committee.
Immunohistochemistry
Tumors were excised 24 h after the fourth injection following
euthanization, ﬁxed in 10% formalin, embedded in parafﬁn blocks,
and processed for histological analysis. Expression of hexon and
cleaved caspase-3 were evaluated. Mouse-antiadenovirus hexon
protein (1:200) (Abcam, Cambridge, MA) or rabbit-antihuman
cleaved caspase-3 (1:200) (Cell Signaling, Danvers, MA) Abs were
used to detect hexon or cleaved caspase-3 expression, respectively.
The slides were then washed with PBS, incubated with the stan-
dard ultra-Sensitive ABC peroxidase staining kit (PIERCE), and
detected with diaminobenzidine tetrahydrochloride (DAB) solu-
tion containing 0.006% H2O2. Tissue sections stained without
primary antibodies were used as negative controls. Photographs
were taken with 20x magniﬁcation and analyzed with NIS-
Elements BR 3.0 software (Nikon Instruments, Inc.).
Statistical analysis
One- and two-way ANOVA was used to determine differences
in cell viability across different virus treatments and doses as
appropriate. Statistically signiﬁcant differences between control
(AdLacZ) and active (Adhz60) virus therapy were determined by
the signiﬁcance of the interaction effect of dose and virus. Differ-
ences in cell viability across combination therapies were analyzed
by one-way ANOVA. Post-hoc testing was performed with Tukey’s
adjustment to control for a signiﬁcance level of 0.05. Tumor size
differences between treatment groups were compared over the
course of the experiment using repeated measures ANOVA. Tumor
sizes at the conclusion of the experiment were compared using
one-way ANOVA, and post hoc testing of differences between
groups were adjusted for multiple comparisons using Tukey’s HSD.Acknowledgments
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